Popular Filters
Trials for GVHD Patients
JAK2/IRAK1/CSF1R Inhibitor
Pacritinib for Chronic Graft-versus-Host Disease
Recruiting1 awardPhase 1 & 2
Bethesda, Maryland
This trial tests pacritinib, a capsule taken by mouth, in adults with moderate or severe chronic graft-versus-host disease (cGVHD) that hasn't responded to other treatments. Pacritinib helps by blocking proteins that cause inflammation and immune issues. Participants will take the drug regularly and have periodic check-ups over an extended period.
Extended Ibrutinib Treatment for Non-Hodgkin's Lymphoma
Recruiting3 awardsPhase 4
Burbank, California
This trial provides continued access to ibrutinib for patients who benefited from previous studies and cannot buy it locally. Ibrutinib is an oral medication that stops cancer cells from growing by blocking a protein they need. It is used in the treatment of chronic lymphocytic leukemia and has been studied for its effectiveness in relapsed CLL and as frontline therapy.
Stem Cell Transplant + Chemotherapy for Leukemia and Lymphoma
Recruiting1 awardPhase 1 & 2
Buffalo, New York
This trial is studying how well chemotherapy, total body irradiation, and post-transplant cyclophosphamide work in reducing rates of graft versus host disease in patients with hematologic malignancies undergoing a donor stem cell transplant.
Janus Kinase (JAK) Inhibitor
Ruxolitinib + Panobinostat for Myelofibrosis
Recruiting3 awardsPhase 4
Toronto, Ontario
This trial is looking at the safety of long-term treatment with ruxolitinib alone or in combination with panobinostat in patients who have previously participated in a study sponsored by Novart
Immunosuppressive Agent
Nonmyeloablative Stem Cell Transplant for Sickle Cell Anemia and Thalassemia
Recruiting1 awardPhase 2
Bethesda, Maryland
This trial tests if using low dose radiation and certain drugs can help patients with beta-thalassemia or sickle cell disease better accept donor stem cells. The treatment aims to suppress the immune system to reduce rejection of the new cells.
Trials for Graft-versus-Host Disease Patients
JAK2/IRAK1/CSF1R Inhibitor
Pacritinib for Chronic Graft-versus-Host Disease
Recruiting1 awardPhase 1 & 2
Bethesda, Maryland
This trial tests pacritinib, a capsule taken by mouth, in adults with moderate or severe chronic graft-versus-host disease (cGVHD) that hasn't responded to other treatments. Pacritinib helps by blocking proteins that cause inflammation and immune issues. Participants will take the drug regularly and have periodic check-ups over an extended period.
Extended Ibrutinib Treatment for Non-Hodgkin's Lymphoma
Recruiting3 awardsPhase 4
Burbank, California
This trial provides continued access to ibrutinib for patients who benefited from previous studies and cannot buy it locally. Ibrutinib is an oral medication that stops cancer cells from growing by blocking a protein they need. It is used in the treatment of chronic lymphocytic leukemia and has been studied for its effectiveness in relapsed CLL and as frontline therapy.
Stem Cell Transplant + Chemotherapy for Leukemia and Lymphoma
Recruiting1 awardPhase 1 & 2
Buffalo, New York
This trial is studying how well chemotherapy, total body irradiation, and post-transplant cyclophosphamide work in reducing rates of graft versus host disease in patients with hematologic malignancies undergoing a donor stem cell transplant.
Janus Kinase (JAK) Inhibitor
Ruxolitinib + Panobinostat for Myelofibrosis
Recruiting3 awardsPhase 4
Toronto, Ontario
This trial is looking at the safety of long-term treatment with ruxolitinib alone or in combination with panobinostat in patients who have previously participated in a study sponsored by Novart
Immunosuppressive Agent
Nonmyeloablative Stem Cell Transplant for Sickle Cell Anemia and Thalassemia
Recruiting1 awardPhase 2
Bethesda, Maryland
This trial tests if using low dose radiation and certain drugs can help patients with beta-thalassemia or sickle cell disease better accept donor stem cells. The treatment aims to suppress the immune system to reduce rejection of the new cells.
Trials for HLA Positive Patients
Probiotic
Probiotics for Preventing Graft-versus-Host Disease
Recruiting1 awardPhase 3
Birmingham, Alabama
This trial is testing whether Lactobacillus plantarum, a beneficial bacteria found in foods like yogurt, can prevent a serious gut complication called acute graft versus host disease in young patients receiving stem cell transplants. The bacteria may help by keeping the gut healthy and reducing inflammation. Lactobacillus plantarum has been used in human studies to promote beneficial effects in the immune system, alleviate intestinal disorders, and reduce the risk of cardiovascular disease. The study will compare patients taking Lactobacillus plantarum to those not taking it.
Chemotherapy
Treg-Enriched Stem Cell Transplant for Leukemia
Recruiting1 awardPhase 1
Boston, Massachusetts
This trial is studying a new way to give a haploidentical stem cell transplant (using donor cells that have been enriched with regulatory T cells) to people with relapsed or refractory acute myeloid leukemia or myelodysplastic syndrome.
Immunomodulator
Extended vs Short-Term Abatacept Dosing for Graft-versus-Host Disease
Recruiting0 awardsPhase 2
Boston, Massachusetts
This trial is testing whether an extended dosing regimen of abatacept, when added to standard calcineurin inhibitor + methotrexate-based prophylaxis, will improve outcomes in patients who have received transplants from 7 of 8 HLA matched donors.
Trials for HLA-A Positive Patients
Probiotic
Probiotics for Preventing Graft-versus-Host Disease
Recruiting1 awardPhase 3
Birmingham, Alabama
This trial is testing whether Lactobacillus plantarum, a beneficial bacteria found in foods like yogurt, can prevent a serious gut complication called acute graft versus host disease in young patients receiving stem cell transplants. The bacteria may help by keeping the gut healthy and reducing inflammation. Lactobacillus plantarum has been used in human studies to promote beneficial effects in the immune system, alleviate intestinal disorders, and reduce the risk of cardiovascular disease. The study will compare patients taking Lactobacillus plantarum to those not taking it.
Chemotherapy
Treg-Enriched Stem Cell Transplant for Leukemia
Recruiting1 awardPhase 1
Boston, Massachusetts
This trial is studying a new way to give a haploidentical stem cell transplant (using donor cells that have been enriched with regulatory T cells) to people with relapsed or refractory acute myeloid leukemia or myelodysplastic syndrome.
Immunomodulator
Extended vs Short-Term Abatacept Dosing for Graft-versus-Host Disease
Recruiting0 awardsPhase 2
Boston, Massachusetts
This trial is testing whether an extended dosing regimen of abatacept, when added to standard calcineurin inhibitor + methotrexate-based prophylaxis, will improve outcomes in patients who have received transplants from 7 of 8 HLA matched donors.
Phase 3 Trials
Probiotic
Probiotics for Preventing Graft-versus-Host Disease
Recruiting1 awardPhase 3
Birmingham, Alabama
This trial is testing whether Lactobacillus plantarum, a beneficial bacteria found in foods like yogurt, can prevent a serious gut complication called acute graft versus host disease in young patients receiving stem cell transplants. The bacteria may help by keeping the gut healthy and reducing inflammation. Lactobacillus plantarum has been used in human studies to promote beneficial effects in the immune system, alleviate intestinal disorders, and reduce the risk of cardiovascular disease. The study will compare patients taking Lactobacillus plantarum to those not taking it.
Kinase Inhibitor
Long-term Ibrutinib for Lymphoma
Recruiting2 awardsPhase 3
Lebanon, New Hampshire
This trial aims to provide ongoing access to ibrutinib for patients who have benefited from it in previous studies. Ibrutinib is an oral medication that blocks a protein involved in cancer growth, helping to slow or stop the disease. The study will monitor safety and effectiveness over time. Ibrutinib has been studied extensively and is used to treat various B cell malignancies, including chronic lymphocytic leukemia and mantle cell lymphoma.
Behavioural Intervention
AAT + Corticosteroids for Graft-versus-Host Disease
Recruiting1 awardPhase 3
Stanford, California
This trial will compare the effectiveness of a combination of AAT and corticosteroids to corticosteroids alone as the first treatment for patients at high risk for developing acute GVHD.
Monoclonal Antibodies
Itolizumab + Corticosteroids for Acute Graft-Versus-Host Disease
Recruiting1 awardPhase 3
Duarte, California
This trial is testing itolizumab, an IV medication, in patients with severe aGVHD. It aims to see if itolizumab can better control the immune system and reduce inflammation. Itolizumab has been used in various conditions including psoriasis, rheumatoid arthritis, and COVID-19.
Corticosteroid
Belumosudil + Corticosteroids for Chronic Graft Versus Host Disease
Recruiting1 awardPhase 3
Duarte, California
This trial is testing a new treatment for people with moderate or severe chronic GVHD. It targets newly diagnosed patients who may not respond well to existing treatments. The goal is to manage or reduce the symptoms of chronic GVHD.
Trials With No Placebo
JAK2/IRAK1/CSF1R Inhibitor
Pacritinib for Chronic Graft-versus-Host Disease
Recruiting1 awardPhase 1 & 2
Bethesda, Maryland
This trial tests pacritinib, a capsule taken by mouth, in adults with moderate or severe chronic graft-versus-host disease (cGVHD) that hasn't responded to other treatments. Pacritinib helps by blocking proteins that cause inflammation and immune issues. Participants will take the drug regularly and have periodic check-ups over an extended period.
Extended Ibrutinib Treatment for Non-Hodgkin's Lymphoma
Recruiting3 awardsPhase 4
Burbank, California
This trial provides continued access to ibrutinib for patients who benefited from previous studies and cannot buy it locally. Ibrutinib is an oral medication that stops cancer cells from growing by blocking a protein they need. It is used in the treatment of chronic lymphocytic leukemia and has been studied for its effectiveness in relapsed CLL and as frontline therapy.
Stem Cell Transplant + Chemotherapy for Leukemia and Lymphoma
Recruiting1 awardPhase 1 & 2
Buffalo, New York
This trial is studying how well chemotherapy, total body irradiation, and post-transplant cyclophosphamide work in reducing rates of graft versus host disease in patients with hematologic malignancies undergoing a donor stem cell transplant.
Janus Kinase (JAK) Inhibitor
Ruxolitinib + Panobinostat for Myelofibrosis
Recruiting3 awardsPhase 4
Toronto, Ontario
This trial is looking at the safety of long-term treatment with ruxolitinib alone or in combination with panobinostat in patients who have previously participated in a study sponsored by Novart
Immunosuppressive Agent
Nonmyeloablative Stem Cell Transplant for Sickle Cell Anemia and Thalassemia
Recruiting1 awardPhase 2
Bethesda, Maryland
This trial tests if using low dose radiation and certain drugs can help patients with beta-thalassemia or sickle cell disease better accept donor stem cells. The treatment aims to suppress the immune system to reduce rejection of the new cells.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.